Bioscience at a Crossroads: Access and Benefit Sharing in a Time of Scientific, Technological and Industry Change: The Pharmaceutical Industry

Following is a review of the market and business environment that impacts pharmaceutical R&D and ultimately demand for natural products, including the following elements: global markets and growth, top companies, patent expirations, and industry consolidation.

CBD, 2013

The global pharmaceutical industry is in a time of dramatic transition. Downward pressure on prices from many governments has increased due to the global economic crisis. At the same time, the "patent cliff” has arrived, with patents on many of the most profitable products in all the major companies recently expired or expiring in the next few years.

Demand from emerging markets, in particular China, India and Brazil, is expanding and industry revenues continue to grow, but in recent years new drug launches on the market have declined. Leads and synergies promised by consolidation over the last few decades have failed to materialize, and many believe that decades of mergers and acquisitions have in fact hurt the industry’s competitiveness and ability to innovate.

Full review here.

Tags: Chemical Industry


Other articles you might be interested in:

Vorschau
Guidance on The ISO Management System and the Protection of Biological Diversity
The aim of this guideline is to encourage businesses to integrate the complex concept of protection of biological diversity in their operational (environmental) management planning on a step-by-step basis in order to continuously and systematically reduce any negative effects they may be having on biodiversity.


Vorschau
Dow's plan to bank $1 billion on natural capital by 2025
Dow Chemical hasn’t shared the final results for its 2015 sustainability goals yet, but the company is already looking ahead with a new, ambitious 10-year agenda.


Vorschau
The European Parliament adopts rules that will impact biodiversity based R&D in food and cosmetics sectors
The EU Parliament overwhelmingly adopted new rules on access to genetic resources and fair and equitable sharing of benefits resulting from their utilization (also known as ABS) in the European Union.

Twitter Xing Facebook LInkedIN



A Simple Explanation of Business & Biodiversity!

Featured video

Newsletter



Media Partners